Indication
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Loading your page…
Loading your page…
Hemophilia B
Marketing Authorisation Holder: Swedish Orphan Biovitrum AB (publ)
EMA Authorisation: 12/05/2016
INN: eftrenonacog alfa
AI Drug & Interaction Analysis
Free account required
Ask Osler about Alprolix: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.